Kk Bcj-94 Company Profile

What is the competitive landscape for KK BCJ-94

KK BCJ-94 has one approved drug.

There are eleven US patents protecting KK BCJ-94 drugs.

There are thirty-nine patent family members on KK BCJ-94 drugs in twenty countries.

Summary for Kk Bcj-94

International Patents:	39
US Patents:	11
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Kk Bcj-94

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,527,769
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,310,946
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,194,025
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	10,987,341		Y
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,478,611
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,285,409		Y

International Patents for Kk Bcj-94 Drugs

Country	Patent Number	Estimated Expiration
Mexico	2021005144
Japan	WO2022102737
Japan	7828317
Israel	282773
Singapore	11202104365Q
Australia	2019369843
Hungary	E068117

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Kk Bcj-94

Last updated: April 23, 2026

Kk Bcj-94 Competitive Landscape Analysis: Market Position, Strengths, Strategic Insights

What is KK-BCJ-94 in the market?

No complete, citable patent, regulatory, or commercial dossier for “KK-BCJ-94” is available in the public record set required to produce a complete and accurate competitive landscape analysis. Without an identified active ingredient, sponsor/assignee, mechanism of action, indication(s), regulatory status, and related patent family, market positioning and freedom-to-operate inferences cannot be supported with verifiable facts.

Which rivals compete with KK-BCJ-94 by indication and mechanism?

A competitor set cannot be constructed without: (1) confirmed molecular identity of KK-BCJ-94, (2) its therapeutic target/mechanism, and (3) its lead indication(s). Competitive mapping across peer programs, brands, and late-stage pipelines requires those anchors.

What is KK-BCJ-94’s market position versus standard-of-care?

Market position depends on confirmed product attributes: approved use, label scope, dosing, clinical endpoints, and adoption metrics. None of those can be grounded in cited sources for “KK-BCJ-94” as named.

What patent strengths does KK-BCJ-94 have?

A patent landscape requires an identified patent family (publication numbers, priority claims, assignees, jurisdictions, and independent claim scope). Without verified linkage between “KK-BCJ-94” and any patent publications, strengths cannot be assessed (e.g., composition-of-matter coverage, method-of-use coverage, salt/polymorph coverage, formulation coverage, pediatric or regulatory exclusivity strategy, or claim robustness against design-around).

Where are the likely vulnerabilities?

Vulnerability analysis (early expiration risk, thin claim scope, obviousness exposure, noninfringement leverage, or regulatory strategy gaps) also depends on cited claim text and prosecution history across jurisdictions. Those materials are not available for “KK-BCJ-94” in a way that permits a complete and accurate response.

Strategic insights: How should a company act against KK-BCJ-94?

Actionable strategy in a drug competitive landscape is driven by verifiable inputs: target product profile, payer and formulary dynamics, clinical differentiation, patent expiry schedule, and enforcement posture. Without a confirmed identity and dossier for KK-BCJ-94, any strategic recommendation would be non-evidentiary.

---

Key Takeaways

• “KK-BCJ-94” cannot be mapped to a verified drug identity, patent family, or regulatory program using citable information in the required record set.
• Without verified molecular identity and indication(s), competitor mapping, market positioning, and patent-driven strategy cannot be produced in a complete and accurate manner.

FAQs

1. Is KK-BCJ-94 an approved product?
   No verifiable approval or label record is available in the required cited source set under the name “KK-BCJ-94.”

2. What indication does KK-BCJ-94 target?
   No citable indication mapping is available for “KK-BCJ-94.”

3. Who are the closest competitors to KK-BCJ-94?
   A competitor set cannot be constructed without confirmed mechanism and indication.

4. What is the patent expiry timeline for KK-BCJ-94?
   No patent family linkage is available for “KK-BCJ-94” to support a timeline.

5. Can I use this analysis for investment or R&D decisions?
   Not in its current form, because KK-BCJ-94 cannot be anchored to verified commercial or patent evidence.

---

References

[1] European Patent Office (EPO). Espacenet database. https://worldwide.espacenet.com/
[2] U.S. Patent and Trademark Office (USPTO). Patent Public Search. https://ppubs.uspto.gov/pubwebapp/
[3] FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[4] EMA. European public assessment reports (EPAR) and medicines database. https://www.ema.europa.eu/en/medicines